Viewing Study NCT02402660


Ignite Creation Date: 2025-12-25 @ 2:14 AM
Ignite Modification Date: 2026-03-04 @ 10:46 AM
Study NCT ID: NCT02402660
Status: ENROLLING_BY_INVITATION
Last Update Posted: 2025-04-27
First Post: 2015-03-09
Is Gene Therapy: True
Has Adverse Events: False

Brief Title: Phase 2 Tolerability and Effects of ALK-001 on Stargardt Disease
Sponsor: Alkeus Pharmaceuticals, Inc.
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Stargardt Disease View
None Stargardt Macular Degeneration View
None Stargardt Macular Dystrophy View
None Autosomal Recessive Stargardt Disease 1 (ABCA4-related) View
Keywords: